Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
|Articles|August 29, 2006
New Orleans Now -- Few Doctors in the HouseA Multimedia Special Report
Author(s)Zach Wise
This special report from Zach Wise, a MedPageToday contributing photographer, presents the sights and sounds of New Orleans medicine a year after Hurricane Katrina.
Advertisement
This special report from Zach Wise, a MedPageToday contributing photographer, presents the sights and sounds of New Orleans medicine a year after Hurricane Katrina.
Advertisement
Related to this article
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
4
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
5